Cprx stock forecast bio-pharma indexes confirm sector

Bio-pharma indexes confirm sector tailwinds. Catalyst Pharmaceuticals doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above. CPRX has seen stronger estimate revision activity and sports more attractive valuation metrics than NBIX, so it seems like value investors will conclude that CPRX is the superior option right now. Technical traders using CPRX stock forecast models emphasize the narrow Bollinger bands as a precursor to volatility expansion. Pending quarterly updates could act as catalysts. Short squeeze potential remains modest, given current borrow rates.